FC 084CSA
Alternative Names: FC 084; FC-084CSA; FC084CSA Axl inhibitorLatest Information Update: 19 Jul 2024
At a glance
- Originator FindCure Biosciences (ZhongShan)
- Class Antineoplastics
- Mechanism of Action Axl receptor tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Jul 2024 FindCure Biosciences plans phase I/II trial in Solid tumours (Combination therapy, Second-line therapy and greater, Metastatic disease, Late-stage disease) in China in September 2024 (PO) (NCT06499350)
- 31 May 2024 Adverse events and efficacy data from a phase-I trial in Solid tumours presented at the presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)